Haemonetics (HAE) Research & Development (2009 - 2026)

Haemonetics' Research & Development history runs 18 years deep, the most recent figure standing at $14.4 million for Q1 2026.

• On a quarterly basis, Research & Development fell 21.08% year-over-year to $14.4 million in Q1 2026; TTM through Mar 2026 was $59.8 million, a 4.71% decrease from a year earlier, with the FY2026 full-year figure at $59.8 million, down 4.71% from the prior year.
• Research & Development grew to $14.4 million in Q1 2026 per HAE's latest filing, from $14.2 million in the prior quarter.
• Across five years, Research & Development topped out at $18.3 million in Q1 2025 and bottomed at $10.0 million in Q1 2022.
• The 5-year median for Research & Development is $14.2 million (2024), against an average of $13.9 million.
• Across the five-year window, Research & Development jumped 33.81% in 2022 and retreated 21.08% in 2026, its largest moves.
• Year by year, Research & Development stood at $12.7 million in 2022, then increased by 4.54% to $13.3 million in 2023, then rose by 19.33% to $15.8 million in 2024, then dropped by 10.37% to $14.2 million in 2025, then advanced by 1.83% to $14.4 million in 2026.
• Per Business Quant, the three latest HAE Research & Development figures stand at $14.4 million (Q1 2026), $14.2 million (Q4 2025), and $14.9 million (Q3 2025).